Search Results for: FORMULATION DEVELOPMENT TECHNOLOGY A Novel
Articles
ORAL THIN FILMS - Misconceptions, Advantages & Limitations About an Emerging Drug Delivery System March 31, 2020
Srinivasan Shanmugam, PhD, says due to advancements in the science behind OTF design, as well as the predicted increase in OTF market valuation, this drug delivery system is becoming increasingly popular.
SPECIAL FEATURE - Improving Bioavailability & Solubility: Understand Your Molecule March 3, 2020
Contributor Cindy H. Dubin asked several leading companies about how they are currently overcoming today’s most pressing bioavailability and solubility challenges for their pharma clients.
INTRATUMORAL DELIVERY - Combining Local & Systemic Treatments: Could Immuno-Oncology Finally Enable Local Intratumoral Delivery? March 2, 2020
Lewis H. Bender, MA, MBA, says cancer is a local and systemic disease, and new forms of local treatment, such as intratumoral dosing coupled with systemic immunotherapy, are being explored.
Oculis Announces Positive OCS-01 Phase 2 Data February 14, 2020
Oculis S.A. recently reported positive data from a phase 2 study of OCS-01, a novel eye drop formulation of dexamethasone,...Adare Pharmaceuticals & NLS Pharmaceutics Collaborate to Develop Controlled-Release Candidates January 15, 2020
Adare Pharmaceuticals, Inc. and NLS Pharmaceutics Ltd. recently announced a collaboration to develop mazindol (MZD) CR product candidates for the treatment of….
Appili Therapeutics Enters Commercial Agreement With Saptalis Pharmaceuticals December 4, 2019
Appili Therapeutics Inc. recently announced it has entered into a commercialization agreement with Saptalis Pharmaceuticals LLC on ATI-1501, Appili’s liquid suspension reformulation of the…..
Soligenix Completes Enrollment in its Pivotal Phase 3 Clinical Trial December 4, 2019
Soligenix, Inc. recently announced it has completed patient enrollment in its Phase 3 "Fluorescent Light Activated Synthetic Hypericin" (FLASH) study...CDMO SELECTION - Ready to Launch: Developing Your Biologic With an Eye Toward Commercial Supply November 26, 2019
Stacey Treichler, PhD, believes the development process for new biologics is complex and requires a substantial amount of time and resources, and reviews some of the areas where careful choice of CDMO is key, including cell line development and cGMP manufacturing capabilities, and how an integrated approach can be beneficial.
Foamix Receives FDA Approval for Topical Treatment October 23, 2019
Foamix Pharmaceuticals Ltd. recently announced the US FDA has approved its novel AMZEEQ (minocycline) topical foam, 4%. AMZEEQ, formerly known...Novavax Initiates Pivotal Phase 3 Clinical Trial October 17, 2019
Novavax, Inc. recently announced the initiation of a pivotal Phase 3 clinical trial for NanoFlu, its recombinant quadrivalent seasonal influenza...Credence MedSystems Awarded Gates Foundation Grant to Develop Dual Chamber Drug Delivery Device October 15, 2019
Credence MedSystems, an innovator in injectable drug delivery technology for the biopharmaceutical industry, recently announced it has been awarded a grant from the Bill & Melinda Gates Foundation to support the…..
AGTC & Otonomy Announce Strategic Collaboration to Develop & Commercialize Gene Therapy October 3, 2019
Applied Genetic Technologies Corporation and Otonomy, Inc. recently announced they have entered into a strategic collaboration to co-develop and co-commercialize...WEARABLE DEVICES - Wearable Drug Delivery Applications: Considerations for Adhesive Material Selection & Wear Testing October 1, 2019
Neal Carty, PhD, MBA, and Deepak Prakash, MS, MBA, discuss the broader healthcare and digital health landscape behind wearable device developments and provide a brief overview of two types of wearable applications — insulin pump therapy/continuous glucose monitoring (CGM) systems and wearable drug injectors.
Dance Biopharm Presents Phase 2 Clinical Data Highlighting Rapid Effects of Inhaled Human Insulin September 24, 2019
Dance Biopharm Holdings, Inc., recently presented data from its Phase 2 clinical study of Dance 501, a novel gentle mist formulation of human insulin administered with its….
SPECIAL FEATURE - Injection Devices: Wearables, Connectivity & Patient-Centric Designs Empower Self-Administration September 3, 2019
Contributor Cindy H. Dubin highlights the innovation in injection devices – from wearables to connectivity to varied dose administration – that have occurred in the past year.
Cara Therapeutics Enters Commercial License Agreement With Enteris BioPharma August 21, 2019
Cara Therapeutics, Inc. recently announced it has entered into a non-exclusive commercial license agreement with Enteris BioPharma, Inc. for oral formulation rights to…..
DRGT Completes a Pivotal Phase I Trial; Results Confirm 6X Faster Attainment of Maximum Plasma Levels June 13, 2019
Druggability Technologies Holdings (DRGT) recently announced results from a pharmacokinetic study of their novel formulation of celecoxib (DRGT-46), which achieves faster time to maximum plasma concentration (Tmax) compared to traditional celecoxib capsules.
Foamix Announces Publication of Phase 3 FMX101 Study June 6, 2019
Foamix Pharmaceuticals Ltd. recently announced the peer review publication of the Phase 3 study FX2017-22 (Study 22) in the Journal...DRUG DELIVERY – ENHANZE (®): An Efficient Way to Optimize Biologic Therapies for Subcutaneous Administration April 30, 2019
Michael J. LaBarre, PhD, discusses how the ENHANZE drug delivery technology has the potential to improve the pharmacokinetic profiles of co-administered drugs through increased dispersion, absorption, and bioavailability.
Soligenix Achieves Significant Enrollment Milestone for its Pivotal Phase 3 Clinical Trial April 18, 2019
Soligenix, Inc. recently announced today it has reached a significant milestone in the Phase 3 clinical study (the “DOM-INNATE” study) for SGX942 (dusquetide) in the treatment of oral mucositis in patients with head and neck cancer (HNC).
Company Profiles
Lyophilization Technology, Inc.
Lyophilization Technology, Inc. 30 Indian Drive Ivyland, PA 18974-1431 T: (215) 396-8373 F: (215) 396-8375 E: inquiry@lyo-t.com W: www.lyotechnology.com WHO...DRUG-DEVICE DEVELOPMENT - Exploring the Complexities of Drug-Device Combination Products
Jeremy Guo, Senior Vice President at WuXi Biologics, and colleagues explain that many factors need to be taken into account when producing a Drug-Device Combination Product from development testing to fill/finish and assembly.
